scholarly journals Establishment of a Disease-Specific Graded Prognostic Assessment for Hepatocellular Carcinoma Patients with Spinal Metastasis

Gut and Liver ◽  
2017 ◽  
Vol 11 (4) ◽  
pp. 535-542 ◽  
Author(s):  
Chai Hong Rim ◽  
Chiwhan Choi ◽  
Jinhyun Choi ◽  
Jinsil Seong
Keyword(s):  
Hepatocellular Carcinoma ◽  
Spinal Metastasis ◽  
Prognostic Assessment ◽  
Graded Prognostic Assessment ◽  
Disease Specific

Establishment of disease-specific graded prognostic assessment for patients with hepatocellular carcinoma and spinal metastasis.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 433-433
Author(s):  
Chai Hong Rim ◽  
Chiwhan Choi ◽  
Jinhyun Choi ◽  
Jinsil Seong
Keyword(s):  
Hepatocellular Carcinoma ◽  
High Risk ◽  
Group Performance ◽  
Spinal Metastasis ◽  
Performance Status ◽  
Survival Rates ◽  
Eastern Cooperative Oncology Group ◽  
High Risk Patient ◽  
Prognostic Assessment ◽  
Graded Prognostic Assessment

433 Background: Spinal metastasis (SM) of hepatocellular carcinoma (HCC) is a crucial clinical problem. It shows heterogenous length of survival suggesting a need for predicting prognosis. In this study, we aimed to develop and propose a graded prognostic assessment of SM of HCC (HCC-SM GPA). Methods: We previously reported the outcomes of 192 HCC patients with SM who received radiotherapy from April 1992 to February 2012. Prognostic factors with significant effects on survival in that study were used to establish the HCC-SM GPA. Validation was performed using an independent cohort of 63 patients recruited from September 2011 to March 2016. Results: We developed HCC-SM GPA using the following factors: Eastern Cooperative Oncology Group performance status ( < 2: 0, > 3: 1 point), controlled primary HCC (Yes: 0, No: 2 points), and extrahepatic metastases other than bone (No: 0, Yes: 1 points). Patients were stratified into low (GPA = 0), intermediate (GPA = 1–2), and high risk (GPA = 3–4). When applied to the validation cohort, the HCC-SM GPA determined median survival durations of 13.6, 4.8, and 2.6 months and 1-year overall survival rates of 58.3%, 8.9%, and 7.3% for the low-, intermediate-, and high-risk patient groups, respectively (p < 0.001). Conclusions: Our newly proposed HCC-SM GPA successfully predicted survival outcome. This index might be a useful tool for making treatment decision.

scholarly journals Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Anna Patrikidou ◽  
Loic Chaigneau ◽  
Nicolas Isambert ◽  
Kyriaki Kitikidou ◽  
Ryan Shanley ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Assessment Index ◽  
Prognostic Assessment ◽  
Graded Prognostic Assessment ◽  
Disease Specific

scholarly journals BM-02 * NEW DISEASE SPECIFIC GRADED PROGNOSTIC ASSESSMENT OF BRAIN METASTASIS FROM LUNG, BREAST, MELANOMA AND RENAL MALIGNANCIES

2014 ◽  
Vol 16 (suppl 5) ◽  
pp. v32-v32 ◽  
Author(s):  
M. Ahluwalia ◽  
V. A. Venur ◽  
M. Chi ◽  
S. Chao ◽  
A. Lilyana ◽  
...  
Keyword(s):  
Brain Metastasis ◽  
New Disease ◽  
Prognostic Assessment ◽  
Graded Prognostic Assessment ◽  
Disease Specific ◽  
Renal Malignancies

scholarly journals An integrated disease-specific graded prognostic assessment scale for melanoma: contributions of KPS, CITV, number of metastases, and BRAF mutation status

2020 ◽  
Author(s):  
Manmeet Ahluwalia ◽  
Mir A Ali ◽  
Rushikesh S Joshi ◽  
Eun Suk Park ◽  
Birra Taha ◽  
...  
Keyword(s):  
Braf Mutation ◽  
Proportional Hazards Model ◽  
Cox Proportional Hazards Model ◽  
Karnofsky Performance Score ◽  
Mutation Status ◽  
Institutional Collaboration ◽  
Prognostic Assessment ◽  
Graded Prognostic Assessment ◽  
Melanoma Patients ◽  
Disease Specific

Abstract Background Stereotactic radiosurgery (SRS) remains a mainstay therapy in the treatment of melanoma brain metastases (BM). While prognostic scales have been developed for melanoma patients who underwent SRS treatment for BM, the pertinence of these scales in the context of molecularly targeted therapies remains unclear. Methods Through a multi-institutional collaboration, we collated the survival patterns of 331 melanoma BM patients with known BRAF mutation status treated with SRS. We established a prognostic scale that was validated in an independent cohort of 174 patients. All patients with BRAF mutations in this series were treated with BRAF inhibitors. Prognostic utility was assessed using net reclassification index (NRI &gt; 0) and integrated discrimination improvement (IDI) metrics. Results In a multivariate Cox proportional hazards model, BRAF mutation status, Karnofsky Performance Score (KPS), number of metastases, and cumulative intracranial tumor volume (CITV) independently contributed to survival prognostication for melanoma patients with SRS-treated BM (p &lt; 0.05 for all variables). These variables were incorporated into a prognostic scale using the disease-specific graded prognostic assessment (ds-GPA) framework. This integrated melanoma ds-GPA scale was validated in two independent cohorts collated through a multi-institutional collaboration. In terms of order of prognostic importance, BRAF mutation status exerted the greatest influence on survival, while KPS, the number of metastases, and CITV exhibited comparable, lesser impacts. Conclusions Optimal survival prognostication for SRS-treated patients with melanoma BM requires an integrated assessment of patient characteristics (KPS), tumor characteristics (CITV and number of metastases), and the mutational profile of the melanoma (BRAF mutation status).

Sign in / Sign up

Export Citation Format

Share Document